Literature DB >> 27660450

Late life bipolar disorder evolving into frontotemporal dementia mimic.

Annemiek Dols1, Welmoed Krudop2, Christiane Möller2, Kenneth Shulman3, Martha Sajatovic4, Yolande Al Pijnenburg2.   

Abstract

OBJECTIVES: Although bipolar disorder has been understood classically as a cyclic disease with full recovery between mood episodes, in the last decade, evidence has accumulated supporting progressive features. The clinical picture of advanced or end-stage bipolar disorder is heterogeneous with possible deficits in cognition and behavior, as illustrated by our case series. CASES: From our neuropsychiatric outpatient clinic, we describe four cases with bipolar disorder gradually developing a clinical syndrome, including apathy, disinhibition, loss of empathy, stereotypical behavior, and compulsiveness, fulfilling the criteria for possible behavioral variant frontotemporal dementia. All cases were diagnosed with bipolar 1 disorder at least 10 years before the onset of the current symptoms, which were not due to recent mood episodes or switches of medication. In all cases, 3-7 years of follow-up yielded no progression. Repeated neuroimaging was within normal limits. Cerebrospinal fluid biomarker studies were not supportive of underlying neurodegenerative pathology. C9orf72 mutation status was negative in all cases.
CONCLUSION: Symptoms fitting the criteria for possible behavioral variant frontotemporal dementia may be present in end-stage of bipolar disorder. An alternative neurodegenerative nature seems unlikely based on repeated normal neuroimaging and the absence of clinical progression. Functional involvement of the frontal-subcortical networks might play a role.

Entities:  

Keywords:  benign phenocopy syndrome; bipolar disorder; bvFTD; older; staging

Year:  2016        PMID: 27660450      PMCID: PMC5019473          DOI: 10.2147/NDT.S99229

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Although bipolar disorder has been classically considered a cyclic disease with full recovery between mood episodes, in the last decade, evidence has accumulated supporting the notion that bipolar disorder is a progressive condition with functional decline over time. In older patients with bipolar disorder, several studies have confirmed a significant cognitive dysfunction1 that was not associated with mood or prodromal phase of dementia.2–6 Similarly, magnetic resonance imaging (MRI) findings in older bipolar patients have shown regional gray matter volume reduction and white matter hyperintensities7–10 that were not consistent with a dementia profile but hypothesized to be correlated with disease duration11 or a result from the toxic effects of recurrent mood episodes.12 The cognitive dysfunction and mild structural brain alterations seen in patients with bipolar disorder suggest a model of accelerated aging.13–16 The clinical stages of bipolar disorder can range from a latent or asymptomatic form (stage 0) to a chronic, end-stage presentation (stage IV). Accelerated aging defines the later stages of bipolar disorder.14–16 The clinical picture of end-stage bipolar disorder is heterogeneous with possible cognitive and behavioral deficits. Here, we report a series of four male cases diagnosed with bipolar disorder who subsequently developed gradually progressive behavioral and social-emotional changes rather similar to behavioral variant frontotemporal dementia (bvFTD). A neurodegenerative nature of this condition, however, could not be demonstrated after 3–7 years of extensive clinical follow-up. We propose that a nonprogressive frontal lobe syndrome constitutes a possible manifestation of end-stage bipolar disorder.

Cases

The Medical Ethical Committee of the VU Medical Centre, Amsterdam, approved the study. All patients provided written informed consent to publish patient data. As a tertiary neuropsychiatric center, we have specialized in diagnosis of patients presenting with behavioral symptoms in later life. All patients undergo a psychiatric, neurological, and neuropsychological examination and an MRI scan at initial presentation. Most patients also undergo a lumbar puncture with determination of cerebrospinal fluid (CSF) biomarkers for neurodegeneration. In each case, a consensus diagnosis is made by a neurologist and a psychiatrist with consecutive follow-up. As we have no possibilities for outreaching care, most of our patients are treated by local mental health organizations or memory clinics. Here, we describe four cases, all alive after a follow-up of 3–7 years.

Case 1

A 78-year-old male, diagnosed with bipolar 1 disorder at the age of 18, was referred to our memory clinic because of gradually progressive behavioral change. Although the patient had no complaints, his wife described changes starting several years ago consisting of excessive consumption of cheese, diminished empathy, and sitting on the couch all day smoking excessively. Over the years, he began to masturbate in public and demonstrated excessive clock watching. He lost the ability to spontaneously initiate conversations and echoed other people’s words. Over time, he developed urinary and fecal incontinence due to personal neglect. His family history revealed a brother with schizophrenia and several first degree family members with depression (Table 1).
Table 1

Characteristics of the four cases

Case 1Case 2Case 3Case 4
Clinical and sociodemographic characteristics
Age (years)78706562
SexMaleMaleMaleMale
Education in years6111313
Age at onset bipolar disorder (years)18535128
Number of admissions312>2
Family history (First degree)PsychiatryCardiovascularCardiovascularCardiovascular
Somatic historyDiabetesMyocardial infarctionChronic obstructive pulmonary diseaseDiabetes
PsychopharmacaLithium 800 mgZuclopentixol 6 mgLithium 1,200 mgQuetiapine 400 mgPhenelzine 45 mgTemazepam 20 mgOxazepam 50 mgLithium 800 mgOlanzapine 2.5 mg
Rascovsky criteria
Disinhibition++++
Apathy++
Loss of empathy++
Stereotypical behavior++++
Eating behavior++
Executive dysfunction++
Neuropsychology
MMSE at presentation28252728
MMSE after follow-up29292329
FAB14121817
FAB after follow-up12171518
Mental speed/attentionSlightly decreasedSlightly decreasedDecreasedNormal
Executive tasksMildly disturbedMildly disturbedMildly disturbedNormal
Episodic memoryNormalMildly disturbedNormalNormal
Semantic memory (category fluency)NormalMildly disturbedNormalNormal
Visuospatial functionsNormalNormalNormalNormal
LanguageNormalNormalNormalNormal
Social cognition
Social cognition profile (faux pas, Eckman faces)n/aImpaired, no recognition of faux pas, impaired recognition of disgustImpaired, no recognition of faux pas, impaired recognition of sadnessImpaired recognition of sadness
Biomarkers
MRI: Fazekas1100
MRI: MTA0/01/10/01/1
MRI: GCA01Frontal 2, parietal 1, global 10
FDG-PETNormaln/aNormalNormal
PIB-PETn/an/aNormaln/a
CSF: amyloid beta-421,071632n/a880
(>550 pg/mL)
CSF: tau (<375 pg/mL)400202n/a486
CSF: P-tau (<52 pg/mL)5836n/a66

Abbreviations: CSF, cerebrospinal fluid; FAB, frontal assessment battery; FDG-PET, [18F]-2-deoxy-2-fluoro-d-glucose positron emission tomography; GCA, global cortical atrophy; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; +, present; n/a, not applicable; PIB-PET, Pittsburgh compound B positron emission tomography; P-tau, phosphorylated tau.

He had previously been admitted three times, but his mood had been stable for over 10 years with use of lithium and zuclopentixol. There was no concurrent mood or psychotic symptoms. Lithium serum levels were within the therapeutic range (0.4–0.8 mmol/L) and a dose reduction did not change his behavior. Mild extrapyramidal features on the neurological examination were attributed to medication use. With respect to cognitive performance, memory problems were not reported, but his spatial orientation was impaired. Mini-Mental State Examination (MMSE) was 27/30 and frontal assessment battery (FAB) was 14/18. At neuropsychological examination, a predominant executive dysfunction was found. Repeated MMSE and FAB scores were 29/30 and 12/18, respectively, after 5 years. Repeated MRI of the brain yielded no abnormalities and [18F]-2-deoxy-2-fluoro-d-glucose positron emission tomography (FDG-PET) scans were repeatedly normal. CSF levels of tau and phosphorylated tau were slightly elevated, with normal CSF level of amyloid beta-42. There were no mutations found in the Microtubule-Associated Protein Tau (MAPT)-gen, progranulin (GRN)-gen, or Presenilin-1 protein (PSEN1)-gen, nor a repeat expansion in the chromosome 9 open reading frame 72 (C9ORF72)-gen. After 7 years of follow-up at our memory clinic, it was concluded that this very slowly progressive frontal syndrome was not due to bipolar mood symptoms or a neurodegenerative disease, such as bvFTD.

Case 2

A 70-year-old male attended our memory clinic because of forgetfulness and word-finding difficulties of 4 years’ duration. He had been diagnosed with bipolar 1 disorder 17 years ago after a serious suicide attempt and successfully stabilized with lithium (Table 1). Three years ago, these same memory complaints made him discontinue lithium abruptly, and a depressive relapse followed. At initial memory clinic presentation, he was on carbamazepine and mirtazapine, without any significant mood symptoms. His wife and daughter reported a gradual change of behavior while his mood was euthymic. He became more focused on religion, impulsively bought a car, and lived by a rigid daily routine. Moreover, inappropriate social behavior was reported, such as visiting the swimming pool without his dentures. There was a gradual loss of empathy. His family history was negative for psychiatric disorders, but positive for dementia in two grandmothers. On examination using standardized rating scales, his MMSE was 25/30 and FAB 12/18. He exhibited a moderate score on the stereotypy rating scale (SRI 8/60). Repeated neuropsychological examination revealed nonprogressive mild executive and episodic memory disturbances with decreased mental speed. His MMSE was 29/30 after 6 years, with a FAB score of 17/18. MRI scans of the brain were repeatedly within the normal range for his age. CSF levels of amyloid beta-42, tau, and phosphorylated tau were all within the normal range. After a follow-up of 6 years, his behavior remained stable and could not be attributed to bipolar mood symptoms or a neurodegenerative disease, such as bvFTD.

Case 3

A 65-year-old male reported no complaints when visiting a memory clinic, although he admitted that he had always been controlling and compulsive, with an urge of excessive cleaning. He had been diagnosed with bipolar disorder and obsessive compulsive personality disorder more than 10 years ago and had been stable on a MAO inhibitor (Table 1). In the last year, he experienced vivid visual hallucinations that initially started during acute medical illness (repeated bout of pneumonia) but persisted after resolution of the medical events at night. His wife and daughter reported increased obsessive compulsive behavior with verbal aggression toward strangers if his routine got disturbed. Furthermore, he tried to force his wife to excessively buy items and was increasingly snacking. His daughter noticed that he had very little interest in others and did not take initiative in social contact nor did he seem to notice the needs of others. His family history was negative for psychiatric disorders and dementia. At neurological examination, there were no extrapyramidal signs. His MMSE was 27/30 and FAB 18/18. He had a high score on stereotypical symptoms (SRI 20/60), which according to his family could not be attributed to his premorbid personality. Repeated neuropsychological examination revealed very slowly progressive mild executive disturbances with decreased mental speed, with MMSE 23/30 and FAB 15/18. His MRI scans showed nonprogressive frontoparietal atrophy after 3 years of follow-up, while his FDG- and Pittsburgh compound B-PET scans were completely normal. His behavioral symptoms could not be accounted for by obsessive compulsive personality disorder, bipolar mood symptoms, or a progressive neurodegenerative disorder.

Case 4

A 62-year-old male visited our memory clinic with progressive memory complaints. He noticed word-finding difficulties and using wrong words. He had been diagnosed with bipolar 1 disorder 30 years ago and had been hospitalized for bipolar mania 6 months before his memory complaints started (Table 1). His mood was euthymic and controlled with lithium and olanzapine. Lithium serum levels were within the therapeutic range (0.4–0.8 mmol/L) and reducing the dose did not change his behavior. According to his wife, he frequently misused words and his speech had slowed. After recovery from his mania, his social judgment remained impaired (eg, asking a 6-year-old unknown girl to accompany him on a canoe trip, talking excessively during a funeral speech, making personal comments to female strangers). His family history was negative for psychiatric disorders or dementia. Except the presence of a mildly slurred speech, no neurological abnormalities were present. At repeated neuropsychological examination, there were no disturbances, with an initial MMSE 28/30 and FAB 17/18. His MRI scan showed medial temporal atrophy grade 1 on both sides without any other abnormalities, and his FDG-PET was within normal range. His CSF had normal amyloid beta-42 (880 pg/mL), with slightly elevated tau and phosphorylated tau (486 and 66 pg/mL, respectively). After 3 years of follow-up, his mood remained stable. His wife reported that he had regained some of his empathy, but was not at his usual level of concern for others. His speech impairments remained static. Repeated MMSE and FAB scores were 29/30 and 18/18, respectively. A repeated MRI scan after 2 years showed no increase of atrophy. His changed behavior could not be accounted for by progressive neurodegenerative disorder after 3 years of follow-up.

Discussion

We present four older male patients with early- and late-onset bipolar disorder who had behavioral and functional impairment consistent with a frontal lobe syndrome. Their informant-based report suggested that this condition was clinically distinct from symptoms characteristic of these individuals’ previous manic or depressive symptoms. After screening for cognitive and executive deficits, few impairments were found, as shown by relatively high MMSE and FAB scores. At neuropsychological testing, there was only mild impairment in mental speed and executive functions. Most profound was their lack of insight and empathy. All four displayed disinhibition and stereotyped behavior, whereas apathy was a significant feature in two cases. All cases fulfilled the Rascovsky criteria for “possible” bvFTD;17 however, after 3 to 7 years of follow-up, there was no progression to “probable” bvFTD since no significant functional decline over time or progressive frontotemporal deficits on neuroimaging developed. In these cases, the age-related MRI findings and absence of cognitive deficits in multiple domains suggest no comorbid dementia, although we cannot entirely rule out case 2 as having early-stage dementia. Although white matter hyperintensities are frequently reported in older bipolar patients, our cases had low Fazekas scores, indicating that their clinical profile was not related to vascular pathology. Two cases had slightly elevated tau levels suggestive of axonal degeneration. However, their normal amyloid beta-42 levels and lack of progressive deterioration make a neurodegenerative cause unlikely. A similar clinical picture with emotional blunting after manic-depressive episodes has been described in the early 20th century as “dementia maniaco-depressionis”.18 The clinical picture described here does not appear to be just a result of pharmacotherapy. Furthermore, with an average of two admissions in our patients and a disease duration ranging from 14 to 60 years, it is not possible to link presumed toxic effects of mood episodes to their current symptoms. A proportion of bvFTD patients have a slow course with relatively normal neuroimaging, particularly those carrying a C9orf72 repeat expansion.19 This repeat expansion has been found in patients with bipolar disorder preceding FTD;20,21 however, this mutation was not detected in a cohort of 206 patients with bipolar disorder.22 C9orf72 mutations were excluded as a possible cause of the clinical syndrome in our cases. Deficits in emotion recognition and theory of mind have been recognized as hallmarks of bipolar disorder.23 Moreover, they have been reported as an early phenomenon in bvFTD.24,25 Executive disturbances are the most prominent feature in the neuropsychological examination in bvFTD, however executive impairment is common in elderly patients with bipolar disorder as well.26,27 A possible link between bipolar disorder and bvFTD has also been suggested by case reports on patients presenting with manic symptoms as a first manifestation of bvFTD28,29 and patients with a lifetime diagnosis of bipolar disorder evolving into bvFTD.30,31 This large clinical overlap in social cognition, executive disturbances, and behavioral profiles might be explained by the involvement of common functional neuroanatomical networks.32–34 The condition fulfilling criteria for possible bvFTD failing to convert to probable bvFTD over time is labeled benign bvFTD phenocopy syndrome.35,36 These patients exhibit behavioral and functional impairments consistent with a frontal lobe syndrome but fail to progress over time and have no frontal or anterior temporal atrophy or hypoperfusion at follow-up. Although an alternative explanation is generally lacking in these cases, end-stage bipolar disorder may be one of the underlying causes of this syndrome, with a male predominance as in our cases.

Conclusion

To the best of our knowledge, there have been no previous case series of older patients with bipolar disorder illustrating progressive behavioral change culminating in frontal lobe syndrome. In all four cases, behaviors could not be attributed to bipolar mood symptoms and were reported as a distinct loss of insight and empathy with disinhibition and socially inappropriate behavior. In spite of the limitations imposed by our small sample size, confined psychiatric follow-up, and lack of postmortem evaluation to rule out other pathological explanations, the clinical implications of our case series are potentially valuable. The recognition of this phenotype is important for the understanding of brain–behavior relationships, in particular, the pathophysiology of bipolar disorder. Our case series is a reminder that clinicians should reject a diagnosis of bvFTD in patients with bipolar disorder in the absence of obvious clinical and radiological progression over time.
  35 in total

1.  Caudate volume measurement in older adults with bipolar disorder.

Authors:  John L Beyer; Maragatha Kuchibhatla; Martha Payne; Melissa Moo-Young; Frederick Cassidy; James MacFall; K Ranga R Krishnan
Journal:  Int J Geriatr Psychiatry       Date:  2004-02       Impact factor: 3.485

2.  Clinical staging: a heuristic model for psychiatry and youth mental health.

Authors:  Patrick D McGorry; Rosemary Purcell; Ian B Hickie; Alison R Yung; Christos Pantelis; Henry J Jackson
Journal:  Med J Aust       Date:  2007-10-01       Impact factor: 7.738

Review 3.  A quantitative review of neurocognition in euthymic late-life bipolar disorder.

Authors:  Cecilia Samamé; Diego J Martino; Sergio A Strejilevich
Journal:  Bipolar Disord       Date:  2013-05-07       Impact factor: 6.744

4.  Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?

Authors:  Gianluca Floris; Giuseppe Borghero; Antonino Cannas; Francesca Di Stefano; Maria R Murru; Daniela Corongiu; Stefania Cuccu; Stefania Tranquilli; Maria G Marrosu; Adriano Chiò; Francesco Marrosu
Journal:  J Neurol       Date:  2013-01-13       Impact factor: 4.849

5.  Neurocognitive functioning in early-onset and late-onset older patients with euthymic bipolar disorder.

Authors:  Diego J Martino; Sergio A Strejilevich; Facundo Manes
Journal:  Int J Geriatr Psychiatry       Date:  2012-03-26       Impact factor: 3.485

Review 6.  Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the 'bvFTD phenocopy syndrome'.

Authors:  Christopher M Kipps; John R Hodges; Michael Hornberger
Journal:  Curr Opin Neurol       Date:  2010-12       Impact factor: 5.710

7.  Relapsing-remitting behavioural variant of frontotemporal dementia in a bipolar patient.

Authors:  Florence Vorspan; Maxime Bertoux; Clara Brichant-Petitjean; Bruno Dubois; Jean-Pierre Lépine
Journal:  Funct Neurol       Date:  2012 Jul-Sep

8.  Clinical implications of a staging model for bipolar disorders.

Authors:  Flávio Kapczinski; Vasco Videira Dias; Marcia Kauer-Sant'Anna; Benicio Noronha Frey; Rodrigo Grassi-Oliveira; Francesc Colom; Michael Berk
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

9.  Cognitive impairment in early and late bipolar disorder.

Authors:  Sigfried N T M Schouws; Hannie C Comijs; Max L Stek; Jack Dekker; Frits Oostervink; Paul Naarding; Iet van der Velde; Aartjan T F Beekman
Journal:  Am J Geriatr Psychiatry       Date:  2009-06       Impact factor: 4.105

10.  Social reasoning, emotion and empathy in frontotemporal dementia.

Authors:  Sinclair Lough; Christopher M Kipps; Cate Treise; Peter Watson; James R Blair; John R Hodges
Journal:  Neuropsychologia       Date:  2005-09-28       Impact factor: 3.139

View more
  9 in total

Review 1.  A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia.

Authors:  Camila Nascimento; Villela Paula Nunes; Roberta Diehl Rodriguez; Leonel Takada; Cláudia Kimie Suemoto; Lea Tenenholz Grinberg; Ricardo Nitrini; Beny Lafer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-04-20       Impact factor: 5.067

Review 2.  Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder.

Authors:  Peijun Chen; Annemiek Dols; Soham Rej; Martha Sajatovic
Journal:  Curr Psychiatry Rep       Date:  2017-08       Impact factor: 5.285

3.  An Algorithm to Characterize a Dementia Population by Disease Subtype.

Authors:  Jennifer S Albrecht; Maya Hanna; Rhonda L Randall; Dure Kim; Eleanor M Perfetto
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Apr-Jun       Impact factor: 2.703

Review 4.  Bipolar Disorder Among Patients Diagnosed With Frontotemporal Dementia.

Authors:  Mario F Mendez; Leila Parand; Golnoush Akhlaghipour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-06-05       Impact factor: 2.198

5.  Manic behavior and asymmetric right frontotemporal dementia from a novel progranulin mutation.

Authors:  Mario F Mendez
Journal:  Neuropsychiatr Dis Treat       Date:  2018-02-26       Impact factor: 2.570

6.  Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit.

Authors:  Manuel Menéndez-González; Tania Álvarez-Avellón; José M Salas-Pacheco; Benito de Celis-Alonso; Kathryn A Wyman-Chick; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2018-05-24       Impact factor: 4.003

Review 7.  Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review.

Authors:  Elizabeth Sakamoto Valente; Paulo Caramelli; Leandro Boson Gambogi; Luciano Inácio Mariano; Henrique Cerqueira Guimarães; Antônio Lúcio Teixeira; Leonardo Cruz de Souza
Journal:  Alzheimers Res Ther       Date:  2019-04-01       Impact factor: 6.982

Review 8.  Frontotemporal Dementia and Late-Onset Bipolar Disorder: The Many Directions of a Busy Road.

Authors:  Mari N Maia da Silva; Fábio Henrique de Gobbi Porto; Pedro Maranhão Gomes Lopes; Catarina Sodré de Castro Prado; Norberto Anízio Ferreira Frota; Candida Helena Lopes Alves; Gilberto Sousa Alves
Journal:  Front Psychiatry       Date:  2021-12-02       Impact factor: 4.157

9.  Qualitative Assessment of Longitudinal Changes in Phenocopy Frontotemporal Dementia.

Authors:  Rozanna Meijboom; Rebecca M E Steketee; Lize C Jiskoot; Esther E Bron; Aad van der Lugt; John C van Swieten; Marion Smits
Journal:  Front Neurol       Date:  2019-11-14       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.